Current use and future potential of organometallic radiopharmaceuticals

@article{Schibli2002CurrentUA,
  title={Current use and future potential of organometallic radiopharmaceuticals},
  author={Roger Schibli and August P. Schubiger},
  journal={European Journal of Nuclear Medicine and Molecular Imaging},
  year={2002},
  volume={29},
  pages={1529-1542}
}
Contrary to common belief, organometallic compounds exhibit remarkable stability in aerobic and even diluted aqueous solutions. Technetium-sestamibi (Cardiolite) is one of the most prominent examples of this class of compounds routinely used in nuclear medicine. This review summarises the recent progress in labelling of biomolecules with organometallic complexes for diagnostic and therapeutic application in radiopharmacy and exemplifies in detail developments focussing on organometallic… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 38 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 60 references

Preclinical evaluation of a new , stabilized neurotensin ( 8 – 13 ) pseudopeptide radiolabeled with Tc99 m

  • E Garcia-Garayoa, P Bläuenstein, +5 authors AP Schubiger
  • J Nucl Med
  • 2002

Stabiliza - tion of neurotensin analogues : effect on peptide catabolism , biodistribution and tumor binding

  • M Brühlmeier, E Garcia-Garayoa, +5 authors P Bläuenstein
  • Nucl Med Biol
  • 2002

99 mTclabeled neuropeptide Y analogues as potential tumor imaging agents

  • M Langer, R LaBella, E Garcia-Garayoa
  • Bioconjugate Chem
  • 2001

A preliminary comparison of methods for production of 188 ReC 595 antibodies for radioimmunotherapy of bladder cancer

  • A Murray, DP Scholfield, +4 authors AC Perkins
  • J Label Compd Radiopharm
  • 2001

Characterization of Tc99 mtricarbonyl complexes as transporter substrates of the multidrug resistance ( MDR 1 ) P - glycoprotein

  • M Dyszlewski, H Blake, J Dahlheimer, D Piwnica-Worms
  • J Label Compd Radiopharm
  • 2001

Similar Papers

Loading similar papers…